AstraZeneca’s Klygefa Approved in US and Europe for Myasthenia Gravis
AstraZeneca said its rare disease unit received approval for Klygefa in the US and Europe for myasthenia gravis.
Story updates
09:04:19 AM UTC
SquawkNews
The approvals from the European Commission and the Food and Drug Administration mark an important milestone for the therapy, which Astrazeneca said was the first and only approved dual-binding nanobody C5 inhibitor in both markets. Klygefa was administered through a once-weekly subcutaneous injecti…